Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 27th Preview)
-
PTSD and psychiatric innovation via neuroplasticity
Otsuka Pharmaceutical moved into experimental psychiatry by announcing a $700 million acquisition of Transcend Therapeutics through its U.S. subsidiary, Otsuka America. The deal could add up to $525 million in milestones tied to sales performance, with closing expected between April and late June. Transcend’s lead asset, TSND-201 (methylone), is designed to rapidly enhance neuroplasticity by engaging specific transporter proteins linked to serotonin, norepinephrine, and dopamine signaling. The company positions the approach as distinct from classic MDMA-like mechanisms, including an emphasis that it does not target the serotonin receptor tied to hallucinogenic effects. The rationale is reinforced by recently published mid-stage data in JAMA Psychiatry in adults with PTSD. Transcend is now enrolling a Phase 3 program in the U.S., and Otsuka is effectively underwriting a late-stage development push behind a potentially paradigm-shifting PTSD therapy.
-
Regulatory approval for rare-disease gene therapy
The FDA granted accelerated approval to Rocket Pharmaceuticals’ gene therapy Kresladi for severe leukocyte adhesion deficiency type 1 (LAD-1), clearing a pathway after an earlier rejection tied to manufacturing concerns. The therapy is intended for children who lack a matched sibling for stem cell transplant. Rocket’s approval follows a 2024 FDA refusal centered on manufacturing issues, underscoring how technical compliance can become the gating factor for late-stage gene therapy programs. While Rocket has positioned the drug for clinical benefit in an ultra-rare population (estimated around 25 new cases per year), investors have generally viewed Kresladi as more strategic than a near-term revenue engine. Clinically, the decision matters because it validates Rocket’s ability to remediate production constraints and re-enter regulatory review in a disease area where there are limited therapeutic options.
-
Immunology dealmaking to refresh Xolair-era allergy pipeline
Novartis agreed to acquire Excellergy in a deal valued at up to $2 billion, targeting next-generation anti-IgE immunology programs that could extend the franchise as Xolair faces biosimilar pressure. The acquisition centers on Excellergy’s lead candidate Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase I evaluation. Novartis said Exl-111 is designed to drive faster and deeper suppression of IgE signaling by targeting receptor-bound IgE to enable FcεRIα downregulation. The company is framing Excellergy as a complement to its existing allergy portfolio, while timing the move against the broader competitive dynamics in IgE-mediated diseases. The companies expect closing in the second half of 2026, subject to regulatory approvals and standard closing conditions, as Novartis works to strengthen its immunology pipeline in the face of impending commercial transitions for established blockbusters.
-
FDA approval expands brain-penetrating protein therapy platform
Denali Therapeutics received FDA approval for Avlayah, a therapy for Hunter syndrome that leverages Denali’s proprietary delivery technology designed to cross the blood-brain barrier. The approval adds to a growing set of FDA decisions for therapies that can reach the central nervous system in rare neurological conditions. Denali’s platform approach is intended to enable systemic administration of biologics while improving access to brain targets—an area that has historically limited treatment options for MPS disorders. The decision arrives after a period of scrutiny and tightening expectations for rare-disease programs, making regulatory success a key signal for the platform’s translational credibility. For developers, the approval reinforces the commercial and scientific value of delivery systems that reliably reach hard-to-access tissues, particularly in pediatric neurodegenerative and neuroinflammatory diseases where outcomes can hinge on CNS exposure.
-
CRISPR patent fight heads back into focus after USPTO reaffirmation
Editas Medicine said the USPTO reaffirmed an earlier decision supporting broad inventorship priority for CRISPR/Cas9 genome editing in a dispute involving the Broad Institute and other institutions. The update keeps the patent question in active view for a core area of commercial gene editing. The case traces to a 2022 Patent Trial and Appeal Board decision finding that Feng Zhang, the Broad Institute, MIT, and Harvard were first to invent CRISPR/Cas9 use in eukaryotic cells, including human cells. In response, the University of California, the University of Vienna, and Emmanuelle Charpentier sought a patent interference in 2015, and the Federal Circuit previously sent the case back to the PTAB for reevaluation. Editas licenses foundational CRISPR/Cas9 intellectual property from the Broad and said the reaffirmation strengthens confidence as it advances in vivo gene editing candidates, including EDIT-401, which the company says has shown more than 90% mean LDL cholesterol reduction in non-human primates.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.